AUSTIN, Texas and MINNEAPOLIS — Luminex Corporation (NASDAQ: LMNX) andBio-Techne Corp (NASDAQ: TECH) today announced the signing of a new distribution and supply agreement through 2020. This agreement extends the relationship between the two companies for immunoassay development and commercialization of Bio-Techne biological content using the Luminex testing platform. Furthermore the agreement allows Bio-Techne to distribute Luminex multiplexing instrumentation, including the Luminex™ 200®, FLEXMAP 3D® and the MAGPIX® platforms in major markets worldwide.

“We are very pleased to broaden our relationship with Bio-Techne, a leading global player in the research, diagnostics and clinical controls markets. We believe enabling Bio-Techne to develop assay content and distributeLuminex multiplexing instruments will aid our goal of providing laboratories of all sizes access to multiplexing solutions for a range of applications,” said Todd Bennett, VP, Global Sales and Customer Operations, Luminex Corporation. “With its global scope, Bio-Techne is an ideal partner that can ensure our advanced multiplexing solutions reach the right scientists and researchers. This partnership will help accelerate science and improve the efficiency of disease-related research around the world.”

“We have been a partner with Luminex for many years and given our strong market position in immunoassay applications, it is logical for Bio-Techne to continue to support our customers with complete customized workflow solutions, including instruments. This is consistent with the Company’s strategic direction of providing full solutions in the Life Science research space, including both biological content and instruments,” said Gerry Andros, VP of Sales for Bio-Techne Corporation.

Financial terms were not disclosed.

About xMAP-based Instruments

Luminex offers three multiplex instruments enabling laboratories to choose a platform that fits their throughput and flexibility needs. MAGPIX is the simplest, most affordable, and most compact of Luminex’s xMAP instruments. This compact multiplexing unit performs up to 50 different tests in a single reaction volume and reads a 96-well plate in just 60 minutes. The Luminex 200 System provides laboratorians the ability to perform up to 100 different tests in a single reaction volume while using either magnetic or polystyrene microspheres. FLEXMAP 3D is the platform of choice for high throughput applications. The platform is capable of simultaneously measuring up to 500 genes or proteins from a small sample. All three xMAP-based instruments run multiplexed assays for both proteins and nucleic acids, whether kit-based or lab-developed.

Learn more about Luminex instruments: www.luminexcorp.com/instruments

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex’s technologies are commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information onLuminex Corporation and the latest advances in multiplexing using award winning technology, please visithttps://www.luminexcorp.com/.